cannabidiol/dronabinol (GWP42002/GWP42003)
/ Jazz
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
March 25, 2015
Epidiolex and Drug Resistant Epilepsy in Children
(clinicaltrials.gov)
- P=N/A; N=N/A; Available; Sponsor: Georgia Regents University
New trial • Biosimilar • Epilepsy
December 09, 2015
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
(clinicaltrials.gov)
- P3; N=120; Active, not recruiting; Sponsor: GW Research Ltd; Recruiting ➔ Active, not recruiting
Enrollment closed • Biosimilar • Epilepsy
November 28, 2015
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
(clinicaltrials.gov)
- P3; N=80; Active, not recruiting; Sponsor: GW Research Ltd; Recruiting ➔ Active, not recruiting
Enrollment closed • Biosimilar • Epilepsy
June 30, 2016
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
(clinicaltrials.gov)
- P2; N=60; Not yet recruiting; Sponsor: University of Colorado, Denver
New P2 trial • Alzheimer's Disease • Biosimilar • Gene Therapies • Parkinson's Disease
July 02, 2015
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome
(clinicaltrials.gov)
- P2; N=30; Active, not recruiting; Sponsor: GW Research Ltd; Trial primary completion date: Mar 2015 ->Jul 2015
Trial primary completion date • Biosimilar • Epilepsy
August 14, 2019
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study
(clinicaltrials.gov)
- P1; N=60; Not yet recruiting; Sponsor: Central Institute of Mental Health, Mannheim; Trial completion date: May 2020 ➔ May 2022; Trial primary completion date: Apr 2020 ➔ Apr 2022
Trial completion date • Trial primary completion date
1 to 6
Of
6
Go to page
1